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Many clinical studies have reported that Buyang Huanwu Decoction (BYHWD) has a protective eﬀect on ischemic heart disease
(IHD). In the present study, the protective eﬀect of BYHWD on myocardial ischemia was investigated. Diﬀerent doses of BYHWD
and Compound Danshen Dropping Pills (CDDP) were lavaged to rats, respectively, isoproterenol (ISO) was intraperitoneally
injected in to all animals to induce myocardial ischemia except the control group. Electrocardiogram (ECG) of each animal was
recorded; activities of lactate dehydrogenase (LDH), creatine kinase (CK) and aspartate aminotransferase (AST) in serum were
detected. As the results of ECG showed, pre-treatment with BYHWD inhibited ischemic myocardial injury, and the activities of
LDH, CK and AST were lower than those in the myocardial ischemia model group, which suggests that BYHWD rescues the
myocardium from ischemia status. To research the potential mechanism, the level of nitric oxide (NO), nitric oxide syntheses
(NOS) and inducible nitric oxide syntheses (iNOS), the expression of iNOS and ligand of cluster of diﬀerentiation 40 (CD40L)
were detected. The results revealed that BYHWD signiﬁcantly decreased the level of NO, NOS and iNOS in serum. Moreover,
BYHWD decreased the expression of iNOS and CD40L in myocardial tissues. These results indicate that the protective eﬀect of
BYHWD on myocardial ischemia and mechanism are associated with inhibition of iNOS and CD40L expression.
1.Introduction
Nitric oxide (NO) is a reactive nitrogen species produced by
nitric oxide syntheses (NOS). Basal generation of NO has
physiological and homeostatic eﬀects, but high level of NO
production is often associated with pathological conditions
[1]. A number of cellular constituents of cardiac muscle,
including the cardiac myocytes, are known to be capable
of expressing inducible nitric oxide syntheses (iNOS) in
response to stimuli [2]. Increasing data support the idea that
iNOS plays a deleterious role in the setting of myocardial
ischemia and infarction [3, 4].
In recent years, inﬂammation has been recognized
as a major force driving ischemic process. Inﬂammatory
cytokines may damage the vascular endothelial surface
directly and lead to ischemia [5]. Increasing evidence
showing that increased level of inﬂammatory markers is
related to ischemic heart disease (IHD) [6]. Furthermore,
several inﬂammatory markers have been used to assess
cardiovascular risks, which aﬃrms that inﬂammation is a
predictor of cardiovascular events recently [7]. In the past
decade,theclusterofdiﬀerentiation40(CD40)anditsligand
(CD40L), as a major factor in chronic inﬂammatory and
autoimmune diseases [8], attracted more and more interest
of the medical community. Some studies demonstrated that
high level of CD40L was associated with increased risk
of cardiovascular events in patients with acute coronary
syndrome. Moreover, healthy women with high levels of
CD40L have been suggested to at an increased risk of
cardiovascular events [9].
InChina,manyformulasandextractscanbeusedtotreat
IHD, Compound Danshen Dropping Pills (CDDP) is the
ﬁrst formula aﬃrmed by US Food and Drug Administration
for its excellent eﬀect on IHD [10]. Buyang Huanwu Decoc-
tion (BYHWD), a well-known traditional Chinese medicine
formula for activating blood circulation to dissipate blood
stasis, has been used for improving neurological functional
recovery in stroke-induced disability in China for centuries2 Evidence-Based Complementary and Alternative Medicine
[11]. Some other studies demonstrated that BYHWD could
down-regulatetheexpressionofiNOSaftercerebralischemia
in mice [12]. Recently, some studies have reported that
BYHWD can be used to treat ischemic coronary heart
disease by relieving angina pectoris [13]. However little is
known about the exact mechanism. In the present study, the
protective eﬀect of BYHWD on myocardial injury induced
by isoproterenol (ISO) in rat was investigated by measuring
theactivities oflactatedehydrogenase(LDH),creatinekinase
(CK) and aspartate aminotransferase (AST) in serum. To
further investigate the potential mechanism, the level of NO,
NOSandiNOSinserum,theexpression ofiNOSandCD40L
in myocardial tissues of this animal model were detected.
2.Materialsand Methods
Trihydroxymethyl aminomethane (Tris) glycine and sodium
dodecyl sulfate (SDS) were purchased from Amresco (Am-
resco, USA). Anti-iNOS antibody was purchased from Bei-
jing Zhongshan Jinqiao Biology Corporation (P.R. China).
Anti-CD40L antibody was purchased from Wuhan Boster
Biology Engineering Corporation (Wuhan, P.R. China).
LDH,CK,AST,NO,NOSandiNOSassay kitswereproduced
by the Institute of Nanjing Jiancheng Biology Engineering
(Nanjing, P.R. China). Protein extraction reagent (RIPA)
kit was purchased from Bioteke Corporation (Beijing, P.R.
China). ISO was purchased from Sigma Biotechnology
(Sigma, USA). CDDP was obtained from Tianshili Pharma-
ceuticals Company (Tianjin, P.R. China). All other agents
used were of the commercially available grade.
2.1. Preparation of BYHWD. BYHWD consists of seven
medicinal components, including Milkvetch Root, Chinese
Angelica, Szechwan Lovage Rhizome, Red Peony Root,
Earth Worm, Peach Seed and Saﬄower, the components
weremixedinorderwiththeratioof120:6:3:4.5:3:3:3
(dry weight). All of the herbal components were originally
purchased from Xi’an Pharmacy of Beijing Tongrentang,
and they were stated above with GAP grade. The drugs
were extracted with standard methods according to Chinese
Pharmacopoeia (China Pharmacopoeia and Committee,
2000). These crude drugs were soaked in distilled water
and boiled for 30min twice, and the drug solution was
ﬁltered through a mesh, then the ﬁltrate was concentrated
to 3gmL−1 by a vacuum pump and stored at 4◦Cu n t i lu s e .
CDDP was used here as a positive control drug.
2.2. Experimental Animals and Model. Sixty male adult
Sprague-Dawley(SD)ratsweighing180–200gwereprovided
by the Medical Experimental Animal Center of Xi’an Jiao-
tong University (Xi’an, P.R. China). The rats were divided
into six groups randomly: control group, model group,
CDDP group (0.073gkg−1/day) and three BYHWD groups
(25.680, 12.840 and 6.420gkg−1/day). When the experiment
began, BYHWD and CDDP were lavaged to the animals
once a day while the control group and the model group
were lavaged with saline for 14 days. From the 12th day,
all animals except those in the control group received ISO
(0.03gkg−1/day) intraperitoneal injection simultaneously
once a day for 3 days, while the control group was injected
with saline. At the end of the experiment, animals were anes-
thetized with intrapentobarbital sodium (0.04gkg−1/day)
by peritoneal injection. After electrocardiogram (ECG) was
recorded, blood samples were collected by cardiac puncture
and heart tissue samples were excised parallel to coronary
sulcus, 3mm apart from cardiac apex. All samples were
frozen in liquid nitrogen immediately for further examina-
tions. The experimental protocol was in accordance with
the National Institutes of Health Guide for Care and Use of
Laboratory Animals and was approved by the Institutional
Animal Care Committee of Xi’an Jiaotong University.
2.3. Determination of the Activities of LDH, CK and AST.
In order to evaluate the extent of heart injury induced by
ISO, the activities of LDH, CK and AST in serum of rats
were measured. When animals were killed, blood sample was
collected and centrifuged at 800rpm for 5min, and then the
serum was collected. The activity of LDH, CK and AST were
detected by pyruvic acid method, N-broncholysin method
and malate dehydrogenase method, respectively. Allthe assay
kits were commercially available and all operations followed
the instructions of the kits. The ﬁndings were detected on an
ultraviolet/visible scanning spectrophotometer.
2.4. Determination of the Levels of NO, NOS and iNOS. The
serum was collected for detection of NO, NOS and iNOS
levels. NO level in serum was detected by nitrate reductase
method while NOS and iNOS level in serum was detected
by chromatometry. All the assay kits were commercially
available and all operations followed the instructions of the
kits. The ﬁndings were detected on an ultraviolet/visible
scanning spectrophotometer.
2.5. Western Blotting. To investigate the potential mecha-
nism, the expression of iNOS in myocardial tissues was
detected byWestern blotting. The total proteinof myocardial
tissues was extracted following the instruction of RIPA and
protein concentration was quantiﬁed with a BCA protein
quantity assay kit. The same amounts of protein was
separated by 10% SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) at 4◦C, and then the protein was transferred
onto microporous polyvinylidene ﬂuoride membranes in
running buﬀer with 20% methanol. After nonspeciﬁc sites
were blocked with 5% milk-Tris-buﬀered saline-tween 20
(TBST), membranes were incubated with anti-iNOS anti-
body (1:400) and anti-β-actin antibody (1:400) at 4◦C
overnight, respectively. Then, membranes were washed with
TBST and a horseradish peroxidase-linked antibody was
employed as a secondary antibody (1:1000), the bands of
interest were detected using an enhanced chemiluminescent
technique. Densities of bands were measured by an image
analyzer.
2.6. Immunohistochemistry. The myocardial tissues samples
w e r es e p a r a t e df r o mt h eh e a r t ,a n dw e r eﬁ x e di n1 0 %
phosphate-buﬀered formalin and embedded in paraﬃnEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Myocardial protective inﬂuence on ECG change in ISO-
induced ischemia: A myocardial ischemia animal model was estab-
lished by giving ISO. CDDP and BYHWD were administered to the
animals. ECG of the animals was recorded. (A) Control group. (B)
Model group. (C) CDDP group (0.073gkg−1/day). (D) BYHWD
group (25.680gkg−1/day). (E) BYHWD group (12.840gkg−1/day).
(F) BYHWD group (6.420gkg−1/day).
and 5μm sections were prepared. For detection of CD40L
expression, sections were incubated with 0.1M citrate buﬀer
(pH 6.0) for 30min at 95◦C for antigen retrieval and
quenching endogenous peroxidase; then the sections were
incubated with horse serum blocking solution for 10min
and treated with rabbit anti-CD40L polyclonal antibody
(1:100) for 2h at room temperature. After being washed
with 0.01M PBS containing 0.05% Tween-20, the sections
were incubated with a biotinylated secondary IgG antibody,
and then the sections were treated with streptavidin perox-
idase and aminoethyl carbazole. Finally, the sections were
visualized with Olympus BX51 microscopy, and the number
of CD40L-positive stained cells in myocardium was counted
at a magniﬁcation of 200x and the ratio of CD40L-positive
stained cells/total myocardial cell was calculated.
2.7. Statistical Analysis. Data are presented as means ± SD.
Statistical analysis was carried out with three or more groups
using one-way analysis of variance (ANOVA) and Dunnetts’
test. The values of P < .05 were considered statistically
signiﬁcant.
3.Results
3.1. Myocardial Protective Eﬀect on ECG Change in ISO-
Induced Ischemia. In order to investigate whether BYHWD
could protect the myocardium from ischemia, ECG of the
animals was recorded by an electrocardiogram recorder. In
the model group, the ECG presented an obvious myocardial
ischemia with a more than 0.lmV of descending at the ST
segment. Pre-treatment with BYHWD (25.680, 12.840 and
6.420gkg−1/day) and CDDP (0.073gkg−1/day) signiﬁcantly
improved the change of ECG by attenuating the descending
of the ST segment (Figure 1).
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Figure 2: BYHWD inhibits the increase of LDH, CK and AST
activities in serum: A myocardial ischemia animal model was
established by giving ISO. CDDP and BYHWD were administered
to theanimals.Theserum concentrationofLDH, CKandASTwere
detected. Resultswere presented asmeans ±SD; ∗P <.05, ∗∗P <.01,
compared with those in the model group.
3.2. BYHWD Inhibited the Increase of LDH, CK and AST
Activities in Serum. The activities of LDH, CK and AST
were increased signiﬁcantly in the model group compared
with those in the control group (P < .01). Pre-treatment
with BYHWD (25.680, 12.840 and 6.420gkg−1/day) and
CDDP (0.073gkg−1/day) could decrease the activities of
these enzymes in serum. The AST activity in BYHWD
of 25.680 and 12.840gkg−1/day and CDDP groups was
signiﬁcantly less than the model group, respectively (P <
.01), and the LDH and CK activities in all drug-used groups
were also less than those in the model group, respectively
(CK, P < .01; LDH, P < .01 or P < .05) (Figure 2).
3.3. BYHWD Inhibited the Increase of NO, NOS and iNOS
Levels in Serum. To determine the potential mechanism by
which BYHWD protects the myocardium from ischemia,
the levels of NO, NOS and iNOS in serum were detected.
The results showed that the levels of NO, NOS and iNOS
in serum were signiﬁcantly increased in the model group
comparedwiththecontrolgroup(P <.01),but,signiﬁcantly
deceased by pre-treatment of BYHWD (25.680, 12.840 and
6.420gkg−1/day) and CDDP (0.073gkg−1/day). Compared
with that in the model group, there was a signiﬁcantly
diﬀerence in the level of iNOS in all BYHWD and CDDP
used groups(P < .01 or P < .05);the diﬀerencesin the levels
of NO and NOS were also signiﬁcant except the BYHWD
6.420gkg−1/day group (P < .01) (Figure 3).
3.4. BYHWD Decreased the iNOS Expression in Myocardial
Tissues. As the results showed, there was few expression of
iNOS protein in the control group whereas it was signiﬁ-
cantlyincreased inthemodel group(P <.01).Pre-treatment
with BYHWD (25.680, 12.840 and 6.420gkg−1/day) and
CDDP (0.073gkg−1/day) could decrease the expression of4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: BYHWD inhibits the increase of NO, NOS and iNOS
levels in serum: A myocardial ischemia animal model was estab-
lished by giving ISO. CDDP and BYHWD were administered to
the animals. The serum concentration of NO, NOS and iNOS were
detected by chromatometry. Results were presented as means ± SD,
∗P < .05, ∗∗P < .01, compared with those in the model group.
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Figure 4: BYHWD decreases the iNOS expression in myocardial
tissues: A myocardial ischemia animal model was established by
giving ISO. CDDP and BYHWD were administered to the animals.
The expression of iNOS in myocardial tissues was detected by
Western blotting. Results were presented as means ± SD. ∗P < .05,
∗∗P < .01, compared with those in the model group.
iNOS in a dose-dependent manner. Compared with that in
the model group, the iNOS protein expression was signiﬁ-
cantly decreased (P < .01) in all BYHWD and CDDP used
groups with an exception of the BYHWD 6.420gkg−1/day
group (Figure 4).
3.5. BYHWD Decreased the CD40L Expression in Myocardial
Tissues. As shown in Figure 5, a few CD40L-positive stained
cells were found in control myocardial tissues. However,
t h en u m b e ro fC D 4 0 L - p o s i t i v es t a i n e dc e l l sw a sr e m a r k -
ably increased in the model group (P < .01). Similarly,
plenty of cells were CD40L-positive stained in BYHWD
6.420gkg−1/day group and there was no diﬀerence in
the ratio of CD40L-positive stained cells/total myocardial
cells between these two groups. In contrast, the number
of CD40L-positive stained cells in the other groups was
decreasedsigniﬁcantly and therewasastatistically signiﬁcant
diﬀerence in the ratio of CD40L-positive stained cells/total
myocardial cells compared with the model group (P < .01).
4.Discussion
BYHWD is a classic traditional Chinese medicine formula
hasbeenwidelyusedfortherapyofischemic cerebraldisease,
such as cerebral ischemia, brain infarction and stroke-
induced disability in clinic [14, 15]. Some studies indicated
that the eﬀects of BYHWD on ischemic cerebral disease were
attributed to its capacity of increasing cerebral blood ﬂow,
decreasing infarction volume, attenuating injury of cerebral
blood vessels and cerebral edema, reducing neural apoptosis
[16, 17]. In recent years, some clinical studies have reported
that BYHWD had the capacity of relieving angina pectoris,
improving myocardial ischemia, decreasing the volume of
myocardial infarction, suggesting that BYHWD can be used
to the therapy of IHD [18, 19].
I nt h ep r e s e n ts t u d y ,t h ep r o t e c t i v ee ﬀect of BYHWD
on myocardial ischemia was investigated by measuring the
change of ECG, as well as the activities of LDH, CK and
AST in serum in a myocardial ischemic animal model
induced by ISO. Usually, ECG is a useful parameter for
determination of myocardial ischemia in clinic and exper-
iment. There are many changes of ECG after myocardial
ischemia, including amplitude of R wave, prolonging of
QRS duration, elevating or descending of ST segment and
change of T wave [20, 21]. The descending of ST segment
reﬂects insuﬃciency of acute coronary circulation or non-
symptomatic myocardial ischemia [22]. In present study, we
found that the ST segment descended after ISO injection
in the model group while the use of BYHWD previously
attenuated this change, suggesting that BYHW prevented
myocardial ischemia induced by ISOin rats. To further study
t h ep r o t e c t i v ee ﬀect of BYHWD on myocardial ischemia,
the activities of LDH, CK and AST in serum were detected.
LDH, CK and AST are mainly present in cytoplasmia of
myocardium and play an important role in myocardial tissue
energy metabolism [23]. CK is an important enzyme for
aerobic metabolism of cells by catalyzing the conversion
of creatine to phosphocreatine. LDH is a key enzyme for
glycolysis that catalyzes the interconversion of lactate and
pyruvate. AST can catalyze the reversible transfer of an
amino groupfrom aspartate to(alpha)-ketoglutaratetoform
glutamate and oxaloacetate [24]. When the myocardium is
injured, these enzymes can be released from the cells to
serum, the activities of these enzymes in serum reﬂect the
extent of myocardium injury. Therefore, the activities of
these enzymes in serum are sensitive biomarkers for heartEvidence-Based Complementary and Alternative Medicine 5
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Figure 5: BYHWD decreases the CD40L expression in myocardial tissues (Bar = 100μm): A myocardial ischemia animal model was
establishedbygivingISO.CDDPandBYHWDwereadministeredtotheanimals.TheexpressionofCD40Linmyocardialtissueswasdetected
by immunohistochemistry, and then the ratio of CD40L-positive stained cells/total myocardial cell was calculated. (a) Control group. (b)
Model group. (c) CDDP group (0.073gkg−1/day). (d) BYHWD group (25.680gkg−1/day). (e) BYHWD group (12.840gkg−1/day). (f)
BYHWD group (6.420gkg−1/day).
injury [20]. As shown in the results, the activities of these
enzymes were signiﬁcantly increased in the model group,
butpre-treatment with BYHWD could signiﬁcantly decrease
the LDH, CK and AST activities in serum, suggesting that
BYHWDcanpreventthemyocardiuminjury inducedbyISO
in rats.
NO is a major regulator for cardiovascular system by
regulating basal vascular tone, blood pressure and tissue
perfusion [25]. There are three mammalian isoforms of
NOS: neuronal NOS (nNOS), inducible NOS (iNOS) and
endothelial NOS (eNOS). NO is usually synthesized by
endothelial nitric oxide synthase (eNOS) in endothelium,
but it also can be produced abundantly by iNOS which
is induced by cytokines and lipopolysaccharide, ischemia,
stroke, trauma, and infection [26]. eNOS and nNOS isoen-
zymes are constitutive and calcium-calmodulin-dependent
enzymes. The former is expressed in the endothelium
underbasal conditions and responsible for the endothelium-
dependentvasodilatation [26],while thelatterisexpressed in
central nervous system and responsible for the mediation of
the metabolism/blood ﬂow coupling into the brain. iNOS is
notconstitutivelyexpressed inheart, butitcanbeinducedby
pathological conditions [27]. Once induced, iNOS is capable
of producing large amounts of NO at 100 times greater than
normal by resident cardiac cells and activated immune cells
that inﬁltrate to the injured heart [28, 29]. Overexpression
of iNOS contributes to myocardial dysfunction and higher
mortality after myocardial infarction, resulting in peroxyni-
trite generation, heart block and sudden death [28], while
inhibition of iNOS improves heart function in myocardial
infarction and reduces infarct size [29, 30]. A recent study
indicates that chronic β-adrenergic receptor stimulation can
upregulate iNOS expression and increase NO production in
the heart, which subsequently markedly enhances forma-
tion of reactive nitrogen species/peroxynitrite in the heart,
thereby eliciting myocardial apoptosis and potentiating
myocardial ischemia/reperfusion injury [31]. In accordance
with these studies, we found that the levels of NO and iNOS
in serum and the expression of iNOS protein in myocardial
tissues were increased signiﬁcantly after ISO injection in the
model group, which implies that NO and iNOS participated
in the development of ischemic myocardial injury. Using
gene knockout animals, increased NO production from
iNOS expression is reported to contribute to myocardial dys-
function and mortality after myocardial infarction in mice
[32]. Selective and continuous inhibition of iNOS can exert
protective eﬀects with respect to myocardial performance,
coronary blood ﬂow, cellular inﬁltration and reduction of
infarct size [3]. In previous studies, it was demonstrated
that BYHWD could improve cerebral ischemia via down-
regulating the expression of iNOS in mice, implying that
iNOS downregulating is a potential mechanism by which
BYHWD improves ischemic diseases [12]. In the present
study, we also found that BYHWD pre-treatment could6 Evidence-Based Complementary and Alternative Medicine
signiﬁcantly decrease the levels of NO and iNOS in serum
and the iNOS expression in myocardial tissues compared
with those in the model group, suggesting that BYHWD
can decrease the NO level in serum by down-regulating the
expression of iNOS after myocardial ischemia induced by
ISO.
Increasing evidence supports that inﬂammation plays
an important role in IHD, including myocardial ischemia
or silent myocardial ischemia [33], and acute coronary
syndromes [34]. Anti-inﬂammatory therapy can modify the
disease process in IHD signiﬁcantly [35]. Many studies
indicate that CD40L plays a role in IHD, and increase of
level of soluble CD40L is a predictor of cardiovascular events
in general populations [36]. In addition, the interaction
of CD40/CD40L plays a dominant role in stimulating of
NO production in murine peritoneal macrophages [37].
Inhibiting the CD40/CD40L interaction may signiﬁcantly
decreaseNOproductioninCD40Lgeneknockoutmice[38].
To further understand the mechanism by which BYHWD
protects myocardial tissues from ischemia, the expression
of CD40L in myocardial tissues were examined. The results
showed that the expression of CD40L was increased sig-
niﬁcantly in myocardial tissues of the model group, while
pre-treatment with BYHWD can signiﬁcantly inhibit the
expression of CD40L, suggesting that anti-inﬂammation by
decreasing the CD40L expression is one of the potential
mechanisms by which BYHWD protects myocardium from
ischemia in rats.
In conclusion, our results suggest that BYHWD has a
protective eﬀect against myocardial ischemia induced by
ISO in rats, and BYHWD inhibition of the iNOS and
CD40L expression in myocardial tissues is the potential
mechanism of this protective action. These ﬁndings provide
a pharmacological basis for the clinical application of tradi-
tional Chinese medicine BYHWD in prevention of ischemic
cardiovascular disease. However, post-treatment with this
decoction whether also could produce a treating eﬀect on
myocardial ischemia is little known. It requires further study.
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